According to the FDA's new drafted guidance on Gonadotropin-Releasing Hormone (GnRH) analogues can treat Advanced Prostate Cancer. The drafted guidance will help sponsors in analyzing the safety and security associated with the GnRH.

A major section of the drafted guidance focuses on the efficiency of the Phase 3 trial considerations that includes dose selection, trial procedures, and timings, efficacy endpoints, and trial population and design. This will help the industry to get the latest information available to proceed further with the development of GnRH.